{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017157","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.851385+00:00","generated_at":"2026-06-16T00:47:56.847447+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Fate Therapeutics Q1 revenue $59M via Janssen termination; cuts workforce, runway to 2H25","bullets":["Q1 GAAP operating expenses $87.6M including $12.9M severance; revenue includes $52.3M from Janssen termination.","Cash, cash equivalents & investments $412.8M; with $13.5M receivables, expects >$300M at year-end 2023.","Discontinued Janssen collaboration, withdrew IND; terminated NK programs FT516, FT596, FT538, FT536.","Workforce reduced to ~220 employees; 2023 GAAP op-ex guidance $265M-$285M.","FT576 enrolling multi-dose cohorts; FT522 IND submitted; FT819 advancing; HER2 IND planned 2H23."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017157","json":"https://secwatch.observer/filing/0000950170-23-017157.json","markdown":"https://secwatch.observer/filing/0000950170-23-017157.md","text":"https://secwatch.observer/filing/0000950170-23-017157.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/0000950170-23-017157-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/fate-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T00:47:56.847447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49d6f46d4f9ea462572bdfb906cbfce6dbbbec3f","claim":"FATE THERAPEUTICS INC reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 3, 2023, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017023017157/0000950170-23-017157-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}